Camurus Celebrates EU Marketing Authorization for Oczyesa®
Camurus (NASDAQ STO: CAMX) has achieved a significant milestone with the marketing authorization for Oczyesa®, a groundbreaking treatment for acromegaly in adult patients who have demonstrated a positive response to somatostatin analogs.
Revolutionary Treatment Delivery
Oczyesa® marks a historic advancement as the first once-monthly, subcutaneous octreotide targeted at managing acromegaly. Designed for effortless self-administration, this innovative treatment utilizes a pre-filled autoinjector pen, simplifying the process for patients.
What is Acromegaly?
Acromegaly is a rare and chronic disorder often resulting from a pituitary tumor that leads to an excess of growth hormone. This condition causes an unfortunate array of symptoms, such as extreme fatigue, joint pain, and the abnormal enlargement of facial features, hands, and feet. Data suggests that around 70,000 individuals in the EU are currently battling with this condition.
Key Features of Oczyesa®
According to Fredrik Tiberg, President & CEO of Camurus, "Oczyesa is a transformative treatment option, offering patients a more convenient way to manage their condition." The product's unique formulation is intended for easy, once-monthly administration, providing patients with greater freedom in their everyday lives.
Clinical Insights and Benefits
Clinical studies, particularly the ACROINNOVA program, showcased Oczyesa's efficiency in controlling acromegaly symptoms. Research indicates that patients using Oczyesa® experience superior biochemical responses, with higher instances of normalized insulin growth factor-1 (IGF-1) levels compared to placebo. Notably, the ACROINNOVA 2 study reinforced these findings, demonstrating sustained symptom reduction and improved quality of life for patients over a 52-week period.
Safety and Efficacy
The marketing authorization is underpinned by robust clinical evidence obtained from a thorough development program comprising seven clinical studies, including two pivotal Phase 3 trials. While most side effects reported were mild and manageable, such as gastrointestinal and nervous system related issues, ongoing monitoring and patient feedback will be essential to ensure safety.
Innovation through Technology
Oczyesa® leverages Camurus' proprietary FluidCrystal® technology, which not only augments drug bioavailability but ensures more reliable dosing schedules, positioning it as a leading option for managing acromegaly effectively.
Camurus' Commitment to Patient Care
Camurus is dedicated to fostering advancements in treatment that can significantly enhance the quality of life for patients affected by chronic ailments. With ongoing operations in Europe, the US, and Australia, the company is expanding its reach with innovative solutions not only for acromegaly but also for other serious health conditions like gastroenteropancreatic neuroendocrine tumors and polycystic liver disease.
The company remains poised for future growth and can address broader medical needs through its commitment to long-acting, innovative therapy solutions. For inquiries or more information regarding Oczyesa®, individuals can reach out to:
Fredrik Tiberg
President & CEO
Phone: +46 (0)46 286 46 92
Email: fredrik.tiberg@camurus.com
Fredrik Joabsson
Chief Business Development Officer
Phone: +46 (0)70 776 17 37
Email: ir@camurus.com
Frequently Asked Questions
What is Oczyesa®?
Oczyesa® is a long-acting, subcutaneous treatment for acromegaly designed for once-monthly administration, improving the patient experience significantly.
How does Oczyesa® work?
It utilizes octreotide to control excess growth hormone levels, providing a more manageable option for patients previously treated with somatostatin analogs.
What are the common side effects?
The most frequently reported side effects include gastrointestinal disorders, nervous system disorders, and injection site reactions, generally manageable with proper care.
How does Oczyesa® compare to traditional treatments?
Oczyesa® is designed for greater bioavailability and patient convenience, demonstrating improved efficacy in clinical trials compared to standard treatments.
What are the aspirations for Camurus moving forward?
Camurus aims to innovate continuously, expanding its treatment portfolio to address various chronic diseases with a commitment to enhancing patient well-being.
